SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Why Queen Kitty ($QKitty) Is The Meme Token You’ve Been Waiting For  Queen Kitty isn’t just another hype project—this is a real movement with substance and community power!  Why hold $QKitty? 😼 Real dev, real builds: No fake teams, no copy-paste code. Everything you see is made from scratch. 💧 Working Faucet: Free QKitty for the community. Want to know how? Just ask! 🏆 Big Buy Competition Bot: See top buyers live, fight for the throne, and win rewards! 🎮 Multi-token P2E game coming soon: Play and earn across Web, iOS, Android! 🐾 NFT collecting soon: Cutest collection in crypto, bringing perks and more ways to earn.  Queen Kitty means innovation, transparency, and real delivery for holders. Curious? Join the chat and ask anything!  $QKitty: By the community, for the community. To the moon, together! 🚀🐱

Queen Kitty

Queen Kitty ($QKITTY) is trending as the community discusses its trading bot, which some users claim generates daily interest. Chatter also mentions upcoming developments like a DEX and swap feature. Some users are reporting losses, while others express bullish sentiment, referring to potential gains.

Trump For President

The Trump Crypto coin is trending amidst mixed sentiment, with some users expressing frustration and others hoping for a turnaround. Community members are discussing the coin's performance, potential links to political figures, and comparing it to other crypto assets. Some traders are speculating on potential upside.

Shibmas was launched on the 9th Of December. The project is a meme token and gives homage to Shiba Inu the token. The token is a playful character who is bringing the Christmas spirit to token holders all around the world. We plan on getting many listings on various exchanges in the coming days. We have over 1000 holders in 24 hours and we aim on getting over 10000 holders within the next week and in the run up to Christmas

Shibmas

Shibmas ($SMAS) is trending, with community members highlighting its potential for a breakout and low market cap. Traders are closely watching key levels and volume, noting positive chart structure and momentum, while also pointing to its availability on Phantom Wallet and association with other meme coins.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express strong conviction in the project's long-term potential within the Solana ecosystem. Discussions highlight its reflexive liquidity model and its potential for significant growth, with many seeing it as more than just a meme coin. Some users are suggesting now is an opportune time to invest.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members discuss its potential to break $200 and reach new highs, with some eyeing a move towards $250. Sentiment around Solana is positive, as many allude to the "WAGMI" (We're All Gonna Make It) mentality. Mentions of potential Solana ETFs are circulating, as well as other Solana-based tokens such as SMAS and WAGMI.

WorldFinancial

$WLFI is trending amidst community discussions around its association with $TRUMP and potential for 'generational wealth.' Some speculate on its regulatory compliance benefits and tokenization of real-world assets, while others express skepticism, citing centralization and lack of utility; the community is split between bullish excitement and bearish concern.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is trending as the community speculates on potential exchange listings and reflects on recent price movement. Some are discussing the possibility of deleting zeros from the price and drawing comparisons to similar meme coin rallies. Community members are actively sharing price predictions and discussing accumulation strategies.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending amid rumors of a potential acquisition by Novartis, which has sparked significant discussion among investors. The community is focused on the potential buyout price and what this may mean for other companies in the RNA therapeutics space. Community members point to strong financials and potential for continued growth and have fueled speculation around other potential suitors.

Just a dead guy

DEADGUY CRYPTO is trending as the community buzzes about its potential, particularly its market cap and possible rise relative to competitors, with some highlighting its position on Phantom Wallet. Many users are sharing the contract address and encouraging others to buy, citing the coin's holder count and potential for substantial returns as a reason for its current momentum.

STMicroelectronics NV is a global semiconductor company, which engages in the business of designing, developing, manufacturing, and marketing products used in a wide variety of applications for automotive, industrial, personal electronics and communications equipment, computers, and peripherals. It operates through the following segments: Automotive and Discrete Group (ADG), Analog, MEMS, and Sensors Group (AMS), Microcontrollers and Digital ICs Group (MDG), and Others. The ADG segment includes dedicated automotive integrated circuits and discrete and power transistor products. The AMS segment offers analog, smart power, MEMS sensors and actuators, and optical sensing solutions. The MDG segment focuses on general-purpose microcontrollers and microprocessors, connected security products, memories, and RF and communications products. The Others segment is involved in sales assembly services and other revenues. The company was founded in June 1987 and is headquartered in Plan-Les-Ouates, Switzerland.

ST Microelectronics - New York Shares

STMicroelectronics NV

STMicroelectronics is trending due to a series of analyst ratings and price target adjustments, sparking discussions around the stock's valuation. Community members are weighing the significance of these expert opinions against the backdrop of the company's initiatives in AI, silicon photonics, and chip manufacturing technology. Investors are also monitoring partnerships and buyback programs.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition

Alkermes inks $2.1B deal to acquire Avadel, adding the latter's Lumryz and new growth potential to its portfolio.

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avadel Pharmaceuticals plc (NASDAQ: AVDL)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avadel Pharmaceuticals plc (NASDAQ: AVDL) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avadel...

Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Avadel Pharmaceuticals plc (NasdaqGM: AVDL) to...

HALPER SADEH LLC ENCOURAGES AVDL, MBCN, FMNB SHAREHOLDERS TO ENFORCE THEIR RIGHTS AND CONTACT THE LAW FIRM

HALPER SADEH LLC ENCOURAGES AVDL, MBCN, FMNB SHAREHOLDERS TO ENFORCE THEIR RIGHTS AND CONTACT THE LAW FIRM HALPER SADEH LLC ENCOURAGES AVDL, MBCN, FMNB SHAREHOLDERS TO ENFORCE THEIR RIGHTS AND...

<ul class="summary-bullets"><li>Alkermes will buy Avadel for up to $20 per share.</li><li>The consideration of $20 values Avadel at about $2.1 billion.</li><li>The deal is expected to close in the first quarter of 2026.<br>&nbsp;</li></ul><p>Alkermes plc (ALKS) and Avadel Pharmaceuticals plc (AVDL) on Wednesday said that the companies have entered into a definitive agreement under which Alkermes will acquire Avadel for up to $20 per share.</p><p>The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-announces-agreement-acquire-avadel-pharmaceuticals">consideration</a> of up to $20 values Avadel at about $2.1 billion and represents a premium of 12% from the stock’s last closing price on Tuesday.</p><h2 class="st-heading-2">How Is The Deal Expected To Impact Alkermes?</h2><p>The total per share consideration includes $18.50 per share, payable in cash at closing, in addition to a contingent value right entitling holders to a potential additional cash payment of $1.50 per share.</p><p>The deal has been approved by the board of directors of both companies and is expected to close in the first quarter (Q1) of 2026. The deal is expected to be accretive upon closing, Alkermes said. The transaction includes Avadel’s Lumryz for the treatment of cataplexy or excessive daytime sleepiness in patients over 7 years of age with narcolepsy, thereby accelerating Alkermes’ entry into the sleep medicine market.</p><h2 class="st-heading-2">What Are Retail Investors Saying?</h2><p><a href="https://stocktwits.com/symbol/AVDL">AVDL stock</a> is up 4% on Wednesday morning. On Stocktwits, retail sentiment around AVDL stock jumped to ‘extremely bullish’ from ‘bearish’ territory over the past 24 hours, while message volume rose to ‘extremely high’ from ‘normal’ levels.</p><p>Avadel launched Lumryz in 2023 and about 3,100 patients are on the therapy as of June 30, the companies noted. Avadel expects net revenues of between $265 million and $275 million in 2025.</p><h2 class="st-heading-2">What Execs Have To Say?</h2><p>The company expects the deal to support Alkermes' portfolio including ALKS 4510 and ALKS 7290 which are currently in early-stage studies. It is also expected to support the advancement of clinical studies to support potential label expansion opportunities for Lumryz currently in late-stage trial in patients with idiopathic hypersomnia.</p><p>“With the acquisition of Avadel, we are able to accelerate our commercial entry into the sleep medicine market at a critical inflection point as we prepare to advance alixorexton into a phase 3 program in narcolepsy.” – Richard Pops, CEO, Alkermes.</p><p>Alkermes expects to finance the acquisition with cash on hand, supplemented by the issuance of new debt.</p><p>AVDL stock is up by 77% this year and by 36% over the past 12 months.&nbsp;</p><p>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-to-recall-nearly-13000-vehicles-in-us/cLG57HOR3q4">Tesla To Recall Nearly 13,000 Vehicles In US, But Retail Has Its Eyes Set On Q3 Earnings</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, an Avadel logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Avadel Stock Rises After Acquisition Offer By Alkermes

Alkermes will buy Avadel for up to $20 per share.

Equity

AVDL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avadel Pharmaceuticals plc Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avadel Pharmaceuticals plc (NASDAQ: AVDL) to Alkermes plc is fair to Avadel shareholders. Under the terms of the...

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc PR Newswire DUBLIN, Oct. 22, 2025 NOT FOR RELEASE...

SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal

Skye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.

ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up

Esperion settles Nexletol and Nexlizet patent dispute with Dr. Reddy's, securing U.S. market exclusivity until 2040 and lifting its shares nearly 14%.

Encompass Health Opens First Connecticut Rehab Hospital in Danbury

EHC opens its first Connecticut rehab hospital in Danbury, boosting its nationwide expansion and meeting rising demand for specialized care.

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals plc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$18.56
Prev Close	$18.56
Open	$18.54
Dividend Yield	0.00%
50-Day Moving Average	$15.29
Beta	0.91
Avg. Volume	1.49M
PE Ratio	-562.42

52-Week High	$18.65
52-Week Low	$6.38
Market Capitalization	$1.8B
EPS (Annual)	-$0.5133
Price to Book	19.80
Revenue Per Employee	$899,558.51
Enterprise Value/EBITDA	N/A

AVDL
Avadel Pharm Sp ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AVDL News

AVDLAvadel Pharm Sp ADR